Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Soticlestat in 15q Duplication Syndrome or CDKL5 Deficiency Disorder
2022-001315-44Phase 2
- Sponsor
- Takeda
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of soticlestat in dup15q syndrome, CDKL5 deficiency disorder (CDD), epileptic encephalopathy and 2 more, sponsored by Takeda. Primary endpoint: Percent change from baseline in motor seizure frequency per 28 days during the Maintenance Period.
02
Drugs
soticlestat
03
Conditions
dup15q syndromeCDKL5 deficiency disorder (CDD)epileptic encephalopathyDravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2022-001315-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001315-44.